Pfizer, BioAtla partner to optimize ADCs

Pfizer Inc. (NYSE:PFE) and BioAtla LLC (San Diego, Calif.) partnered to develop antibodies against cancer using Pfizer's antibody drug conjugate payloads and BioAtla's Conditionally Active Biologics (CAB) technology, which is designed to optimize proteins to be activated or inactivated in select microenvironments.

Pfizer and BioAtla will each hold licenses to the other partner's platform to develop and commercialize optimized ADCs. Both companies are eligible for milestones and royalties from candidates developed and commercialized by the other party. ...